ABSTRACT
INTRODUCTION
Migraine is a common chronic neurovascular disease. Migraine headaches can present with aural neurological symptoms and autonomic nervous system dysfunction (11). Migraine attacks are characterized by numerous changes, including psychological and neurological, and structural or autonomic manifestations. Among patients with migraine, 15% have aura and the presence of 2 attacks of migraine starting with aura leads to the diagnosis. The aural phase, which is usually less than 1 hour in duration, includes positive or negative focal neurological symptoms that lead to or accompany the headache. The most frequent auras are visual, although sensory and motor auras can also be observed. Headaches usually occur within 1 hour after the aura, but can occur later or also may not occur (5) .
Transcranial Doppler ultrasonography (TCD) is a safe and sensitive method for measuring cerebral blood flow velocity (CBFV) in the basal cerebral arteries. TCD can be used to evaluate the flow characteristics of intracranial arteries, microemboli, and vasomotor reactivity (VMR). The acoustic window is the cranial bone's thinnest region for using TCD and the transtemporal window facilitates insonation of the ipsilateral middle cerebral artery (MCA), anterior cerebral artery (ACA), and posterior cerebral artery (PCA) (13, 15, 30, 31) . Neuronal activity is correlated with changes in local cerebral blood flow. As TCD can instantly show hemodynamic changes, it is a great tool for investigating the connection known as vasoneuronal coupling (1, 24) .
Cerebral VMR is the capacity to meet the cerebral circulation and blood flow velocity (decrease and increase) based on cerebral metabolic changes. VMR is important for the autonomic and hemodynamic functioning of the cerebrum (7, 8, 19, 27, 29) and we think that it can be helpful in following up the efficacy of migraine prophylaxis. Topiramate (TPM) is an antiepileptic with broad-spectrum and multiple mechanisms of action, and is used as a prophylactic treatment for migraine (17, 21) . The present study aimed to evaluate the efficacy of TPM treatment on the frequency and duration of migraine attacks, visual analog scale (VAS) score, VMR (from both the right and left MCA, and PCA), and cerebral blood flow in migraine with aura patients.
MATERIAL and METHODS
This study was conducted under permission of institutional review board of "Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey" (Decision #: 1, 25.12.2012).
We included 20 (15 females, 5 males with a mean age of 32.75 years) migraine with aura patients (group 1) and 20 (16 females, 4 males with a mean age of 32.90 years) headachefree control subjects (group 2) in our study. All of the patients fulfilled the diagnostic criteria of migraine established by the Headache Classification Committee of the International Headache Society. The patients and controls provided informed consent to participate in the study. All patients had normal neurological examination findings.
Exclusion Criteria
Patients who had used any kind of prophylactic treatment for headache in the last 3 months, patients who had medication overuse headache according to The International Classification of Headache Disorders (2nd Edition), patients who had received botulinum toxin type A (BoNT-A) therapy, pregnant women or those with a positive urine pregnancy test, patients with a history of malignancy, patients who had a history of cervical and cranial surgery, patients who had ingested more than 500 mg/day caffeine during last month, patients who had received non-pharmacological therapy for the last 6 months, patients with anemia or bleeding diathesis, patients with major psychiatric disorders (major depression etc.), patients who had used antipsychotic, antidepressant and antiepileptic drugs within the previous 3 months, patients with neuromuscular dysfunction, patients using agents that affect neuromuscular functions such as curare or antibiotics like aminoglycoside, patients with uncontrolled hypertension, patients with hypothyroidism or hyperthyroidism, and patients who had a history of primary headaches other than migraine with aura were not included in the study.
Whole blood count, routine biochemical tests, thyroid function tests, and vitamin B12, folic acid, and ferritin level measurements were performed to rule out secondary causes. Computerized Cranial Tomography (CCT) or Magnetic Resonance Imaging (MRI) were used as necessary.
Study Design
20 migraine patients underwent cerebral VMR measurement using TCD imaging of both MCAs and PCAs before and after TPM treatment. 20 controls also underwent VMR measurement with the same technique and by using the same arteries. Recordings were made with the participants in a comfortable supine position, using a DWL Multi-Dop T TCD Doppler instrument. Two 2-MHz pulse-wave probes were affixed to the transtemporal window. Doppler signals from the MCAs were obtained by placing the probe over the temple and adjusting the position for a maximal reflected signal at a depth of 45-60 mm. Additionally, signals from the PCAs were recorded posteriorly and slightly caudally from the MCAs at a depth of 65-70 mm. Breathholding was used to measure VMR in 3 sets. Patients and controls held their breath for 30 seconds and the procedure was continued after 5 minutes of rest.
Cerebral VMR was evaluated according to the breathholding index (BHI). BHI is calculated as follows: mean flow velocity at the end of breathholding -mean flow velocity at rest/mean flow velocity at rest x 100/s of breathholding. Group 1 initially received 25 mg/day of topiramate orally, and then the dose was increased by 25 mg every week. At the fourth week the dose was increased to 50 mg b.i.d. and this dose was continued; transcranial Doppler parameters were re-evaluated 2 months after the treatment. In addition, the number of attacks per month, duration of pain, and visual analog scale (VAS) scores in group 1 obtained before the treatment and 2 months after the treatment were compared.
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Statistical Analysis SPSS v.15.0 was used for statistical analysis. Data are presented as mean ± standard deviation. The Mann-Whitney U and Wilcoxon tests were employed, and a P value <0.05 was considered statistically significant.
RESULTS
20 (15 females, 5 males with a mean age of 32.75 years) migraine with aura patients (group 1) that received TPM and 20 (16 females, 4 males with a mean age of 32.90 years) healthy headache-free controls (group 2) were included in the study. There were no significant differences between the groups according to age and gender (p>0.05).
The number of attacks in group 1 was 6.35±1.98 before treatment and 4.05±1.57 after treatment and this decrease was statistically significant (p=0,01). Group 1's number of painful days was 12.55±5.09 before treatment and 7.85±3.31 after treatment and this decrease was statistically significant (p<0,001). Group 1's VAS scores that show the severity of pain was 86.75±7.82 before treatment and 59.75±18.38 after treatment and this decrease was statistically significant (p<0.001).
The basal flow velocity values obtained from the right and left MCA and PCA before TPM treatment were significantly higher in group 1 than in the control group (p < 0.05). VMR values obtained from the right and left MCA and PCA before TPM treatment were again significantly higher in group 1 than in the control group (p < 0.05). The basal flow velocity recorded from the right and left MCA's, and the VMR values after TPM treatment in group 1 did not differ significantly from those in group 2 (p > 0.05).
The number of attacks, duration of pain, and VAS scores in group 1 were significantly lower after the treatment than before the treatment (p < 0.05). The number of attacks, duration of pain, and VAS scores were not recorded in group 2 as these subjects were headache free. The characteristics of the study population, mean flow velocities, and VMR values are shown in Tables I-III .
DISCUSSION
Prior to TPM treatment in group 1, basal cerebral blood flow velocity obtained bilaterally from the MCAs and PCAs, and VMR were significantly higher than those in the control group (p < 0.05), whereas 2 months after treatment, there were no significant differences in these parameters between the 2 groups (p > 0.05). Additionally, the number of attacks, duration of pain, and VAS scores after treatment in group 1 were significantly lower than the pre-treatment values (p < 0.05). The present findings show that topiramate treatment was effective in migraine with aura patients, and regulated cerebral blood flow velocity and VMR.
Lauritzen reported that blood pressure autoregulation during migraine attacks is normal in all brain regions, but metabolic autoregulation (CO2 reactivity) is impaired in hypoperfused regions, as compared to normally perfused brain regions, after cortical spreading depression (CSD) (18). Nedeltchev et al. reported that migraine patients suffer from an autoregulation disorder, based on flow response behaviour in both MCAs and (31) . Dora and Balkan studied patients with migraine and a control group. They reported that BHI was significantly higher in the patients, and that elevated reactivity might be associated with an increase in vascular tonus; however, normal blood flow velocity and high reactive responses were observed in the patients. These findings suggest that the reactive responses in the migraine patients were due to altered hypersensitivity to CO2 (9). Dora and Balkan also studied 20 migraine patients and 11 healthy controls, comparing BHI before and after 10 mg flunarizine per day treatment. Before treatment BHI values were significantly higher in the migraine group, whereas after 3 months of treatment the difference in BHI was no longer significant (10). Fiermonte et al. reported higher cerebral blood flow velocity in migraine patients with and without aura, and higher VMR in the migraine with aura patients. Following 2 months of flunarizine treatment, VMR in the migraine with aura patients was within normal limits, whereas blood flow rates did not change. Flunarizine reduced VMR without affecting the cerebral blood flow velocity, which indicated that its mechanism of action is not related to vasodilatation (12).
PCAs (using visual stimuli during an attack-free period) (20) . Ayata et al. evaluated the efficacy of prophylactic migraine drugs on CSD using a rat model. Valproate, propranolol, amitriptyline, TPM, and methysergide were administered. They reported that chronic use of these drugs reduced the frequency of CSD (dose dependently) by 40%-80% (6).
It remains unclear via what mechanism TPM acts as a migraine preventive (14) . Storer and Goadsby reported that TPM inhibits neurons of the trigeminocervical complex following superior sagittal sinus stimulation (25) . Shank reported the molecular activity of TPM, as follows: inhibits voltage-gated Na and Ca channels; modulates glutamate-mediated neurotransmission (reducing depolarization induced by AMPA and kainatemediated currents); enhances some types of GABA receptors; inhibits carbonic anhydrase; modulates K conductance and proteins that regulate neurotransmitter release from synaptic terminals (22) . TPM acts by reducing nociceptive transmission via trigeminovascular modulation and inhibition of CSD (2, 25) . Ackerman and Goadsby showed that TPM was also able to inhibit NO-induced dural blood vessel dilation (3). They reported that TPM attenuates the NO response, presumably inhibiting the release of CGRP from trigeminal neurons, but not the NO-cGMP interaction that produces dilation of blood vessels. It seems unlikely that TPM acts directly on dural blood vessels, as it is unable to inhibit CGRP-induced dilation (3).
Thie et al. examined 100 patients (common or classic migraine) using TCD and compared the patients to a control group (40 young controls). They reported that all intracranial arteries in the migraine patients had higher average flow rates, and that the vascular reactivity in the PCAs in response to eye closing was significantly higher in the migraine group than in the control group (26 Kastrup et al. studied 20 migraine patients and 30 controls using TCD of both MCAs and PCAs, and reported that mean cerebrovascular blood flow velocity and CO2 reactivity were higher in the patients with migraine (15) . The same year Kastrup et al. investigated metoprolol treatment and reported that it had no effect on reactivity in migraine patients that had elevated reactivity before treatment (16). Silvestrini et al. evaluated cerebrovascular reactivity in the MCAs and basilar arteries in 15 migraine patients with aura, 15 migraine patients without aura, and 15 healthy controls. VMR obtained from the MCAs was similar in all groups, but VMR obtained from the basilar arteries were lower in the patients with migraine and aura (23).
In conclusion, the literature clearly shows that there is a relationship between migraine and cerebral hemodynamics, especially MCA hemodynamics; however, unlike other studies, the present study used TPM as a prophylactic treatment, the BHI procedure was employed, and both right and left MCA and PCA hemodynamics were simultaneously evaluated. Based on the present study's findings, TPM was efficacious in migraine with aura patients and TPM played a role in the regulation of cerebral hemodynamics.
The limitations of our study is that the number of patients included was relatively small and that it would be better to compare the control group with migraine patients who have not received TPM treatment. Further work is needed to show the relationships between migraine and hemodynamic abnormalities, treatment options, and their effects on cerebral blood flow. Our VMR results and VAS scores showed that TPM is an effective drug for prevention of migraine and reducing the severity of attacks.
